Oddo BHF - Transgene SA (TNG) Transgene : Une pression sur le cours sans justification apparente

Report

Oddo BHF

Martial Descoutures ...

Oussema Denguir

Transgene : Une pression sur le cours sans justification apparente

Les récents résultats cliniques de TG4050 et de BT-001 viennent renforcer les ambitions du groupe à la fois sur les vaccins individualisés et sur les virus oncolytiques. TG4050 devient, selon nous, son actif principal auquel pourraient se rajouter deux autres candidats : BT-001 et TG6050 dont les résultats de phase I sont attendus en 2025. Malgré ces résultats cliniques positifs, nous ajustons significativement notre OC de 2,2 € à 1,4 € pour intégrer essentiellement : 1/ l’avance en compte courant de l’actionnaire majeur TSGH (Groupe Institut Mérieux), et 2/ les résultats décevants de TG4001 ainsi que le décalage en moyenne de deux ans des lancements de TG4050, BT-001 et TG6050. Nous maintenons notre opinion Surperformance, convaincus que le cours actuel n’intègre que partiellement les ambitions du programme de TG4050.

14/01/2025 1 FR

Underlying

Transgene SA

Transgene is a biopharmaceutical company that designs and develops immunotherapy and virotherapy products for the treatment of cancers and infectious diseases. Co. is developing three anti-cancer products that are in clinical trials: (cancer of the lungs, liver and oropharynx); two anti-infectious immunotherapy products also in clinical trials: (hepatitis B and C). Co. also has products in the pre-clinical development stage. Co. operates in a single business segment, the research and development of therapeutic vaccines and immunotherapy products. Co. does not have any products on the market. Substantially all of its operations are conducted in France.

See profile

FR0005175080 Euronext Paris France

Provider

Oddo BHF

Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

See profile

Analysts

Martial Descoutures

Oussema Denguir

Other Reports on these Companies

Oddo BHF

Transgene : Share price under pressure for no apparent reason

The recent clinical results of TG4050 and BT-001 strengthen the group's ambitions for both personalized vaccines and oncolytic viruses. TG4050 becomes, in our opinion, its main compound, to which two other candidates could be added: BT-001 and TG6050 with phase I results expected in 2025. Despite these positive clinical results, we are significantly adjusting our TP from € 2.2 to € 1.4 to factor in mainly: 1/ the current account advance of the major shareholder TSGH (Institut Mérieux Group), and 2/ the disappointing results of TG4001 as well as the average two-year delay in the launches of TG4...

11h / 50m 11h / 50m 1 EN

GlobeNewsWire

Transgene Announces Financial Calendar for 2025

Transgene Announces Financial Calendar for 2025 Strasbourg (France), January 14, 2025, 5:45 p.m. CET—Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces its financial reporting dates for 2025: March 27, 2025: 2024 Fiscal Year Results April 24, 2025: First Quarter 2025 Financial Results May 15, 2025: Annual Shareholders' Meeting September 16, 2025: First Half 2025 Financial Results November 4, 2025: Third Quarter 2025 Financial Resul...

12h / 17m 12h / 17m 1 EN

Transgene : Share price under pressure for no apparent reason

11h / 50m 11h / 50m 1 EN

Pierre François Merveille

Pierre François Merveille

Ipsos : Issuance Focus

French market research company Ipsos (Baa3/Fitch: BBB) aims to issue € 400m of new 5-year unsecured notes. Proceeds from the transaction will be used for general corporate purposes, including the refinancing of the existing € 300m unsecured notes maturing in September 2025. We recommend subscribing to the new bonds at a yield of 3.8% or above (MS+120bp or above).

11h / 56m 11h / 56m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Transgene : Une pression sur le cours sans justification apparente

Transgene : Share price under pressure for no apparent reason

Transgene Announces Financial Calendar for 2025

Transgene : Share price under pressure for no apparent reason

Ipsos : Issuance Focus

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe